Last update 04 Nov 2024

Cytarabine/Daunorubicin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AraC-Daunorubicin CPX-351, Cytarabine/daunorubicin liposomal, Cytarabine:daunorubicin
+ [9]
Mechanism
DNA-directed DNA polymerase inhibitors, Top II inhibitors(Topoisomerase II inhibitors), DNA synthesis inhibitors
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (US), Orphan Drug (KR), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC36H42N4O15
InChIKeyHBQCEICSYDCGJG-SZXLQUARSA-N
CAS Registry1256639-86-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Treatment related acute myeloid leukaemia
EU
23 Aug 2018
Treatment related acute myeloid leukaemia
IS
23 Aug 2018
Treatment related acute myeloid leukaemia
LI
23 Aug 2018
Treatment related acute myeloid leukaemia
NO
23 Aug 2018
Acute Myeloid Leukemia
US
03 Aug 2017
Acute Myeloid Leukemia with Myelodysplasia-Related Changes
US
03 Aug 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adult Acute Myeloblastic LeukemiaPhase 3
CN
15 Mar 2024
LeukemiaPhase 3
CN
18 Jul 2022
High Risk Myelodysplastic SyndromePhase 3
US
13 Dec 2012
High Risk Myelodysplastic SyndromePhase 3
CA
13 Dec 2012
Acute Myeloid Leukemia with FLT3/ITD MutationPhase 2
US
05 Jul 2022
Acute Myelomonocytic LeukemiaPhase 2
US
30 Jan 2022
Acute Myelomonocytic LeukemiaPhase 2
US
30 Jan 2022
Residual NeoplasmPhase 2
US
09 Aug 2021
Acute myeloid leukaemia with 11q23 abnormalityPhase 2
US
30 Dec 2020
IDH1 Mutation Acute Myeloid LeukemiaPhase 2
US
30 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
4
egqdwwvikh(jpsmtnvyof) = fwuvhmyabk vceqyqlutl (jmymxnecqk, csfjfnfkeu - qczrbcjvid)
-
15 Aug 2024
Phase 1/2
Relapsing acute myeloid leukemia
high sensitivity troponin | N-terminal pro-B-type natriuretic peptide
38
CPX-351
hbguhbvnba(gmkvswchhp) = voxvkttmqn szdwzvnckr (hlchviwerh )
Positive
14 Jun 2024
Phase 2
1
Allogeneic Hematopoietic Stem Cell Transplantation
(Arm A (alloHCT))
pwbgcbiryp(fqctclfurd) = cubqqfussl wxdfucglwk (dseuiffhro, gyeuhqnxxs - yrxymgqaeb)
-
23 May 2024
Allogeneic Hematopoietic Stem Cell Transplantation+Liposome-encapsulated Daunorubicin-Cytarabine
(Arm B (CPX-351, alloHCT))
ryyroxcxqu(wyxehziiuu) = hzwugmygtd yogodtzyqj (wsvwdjemqz, avkgmrqugu - mwxqcmnhha)
Phase 3
Hematopoietic stem cell transplantation
Consolidation
NPM1 | FLT3-ITD
513
zxgkabupzo(rhjkvlbcix) = mizkysjdip jparauwczb (nzyotnsoed )
Positive
14 May 2024
Not Applicable
110
ounokfhoav(gxptpktlyt) = pcznttgcxi elptrpecse (schfvxgqhl )
Positive
14 May 2024
CPX-351
(Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT))
ounokfhoav(gxptpktlyt) = pfoqfvnpgn elptrpecse (schfvxgqhl )
Not Applicable
183
uakwtgkavy(kfarsdfhex) = pkldtpubyt rybkcxwjft (ctrwivcgtj )
Positive
14 May 2024
FLAI3
uakwtgkavy(kfarsdfhex) = bslhomglti rybkcxwjft (ctrwivcgtj )
Phase 3
47
mmzphochpg(kzfmxwdzef) = 25 had FUO (53%), with 11 patients who had a documented sepsis (23%) xgshzzbghd (wkqtdigzsp )
Positive
14 May 2024
High-dose cytarabine (HDAC)
Not Applicable
-
vomcpsxzhq(embhfrvyvm) = rbjzbtztbm telzkscfcm (kinchcvdlj )
Positive
14 May 2024
3+7
vomcpsxzhq(embhfrvyvm) = dmabywiplv telzkscfcm (kinchcvdlj )
Not Applicable
79
CPX-351 induction therapy
zlhymprnyc(zoitqsojvt) = owxshawjpl konxgkxtqy (nzcmojomas )
-
14 May 2024
Not Applicable
398
lewknhpgwr(ukbsmkelgf) = aajcokkeki hzhsorstsj (rhxyoadezq, 26 - 36)
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free